Lilly cancer push boosted by survival benefit to key drug

Nearly two years after the first U.S. approval of Eli Lilly's breast cancer drug Verzenio, the company said Tuesday interim data from a Phase 3 study show proof of a survival benefit among women with metastatic disease.